Anomalous rise of serum osteocalcin following desferrioxamine treatment in aluminium intoxication.
A patient with impaired renal function, severe osteomalacia and aluminium intoxication is described. In response to Desferal (desferrioxamine) treatment, serum osteocalcin rose 8-fold whereas serum alkaline phosphatase and procollagen I peptide levels changed little. Chromatographic separation showed that the measured osteocalcin coeluted with intact osteocalcin. The osteocalcin in the serum probably comes from the liberation of pre-existing osteocalcin from the bone, concomitant with aluminium mobilisation, rather than by stimulation of de novo synthesis.
Davie
M W
MW
Charles Salt Research Centre, Robert Jones & Agnes Hunt Hospital, Oswestry, Shropshine, UK.
Worsfold
M
M
Sharp
C A
CA
Perks
J
J
Day
J P
JP
D000535:Aluminum / Q000097:blood / Q000506:poisoning*; D001846:Bone Development / Q000187:drug effects; D002113:Calcification, Physiologic / Q000187:drug effects; D002850:Chromatography, Gel; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D011041:Poisoning / Q000097:blood / Q000188:drug therapy
D015675:Osteocalcin; D000535:Aluminum; D003676:Deferoxamine